Lyudmila F. Gulyaeva

Prof. Dr. Lyudmila F. Gulyaeva

Federal Research Center for Fundamental and Translational Medicine SB RAMS, Novosibirsk, Russia
orcid

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2016 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
Lyudmila F. GulyaevaLyudmila F. Gulyaeva
Lyudmila F. Gulyaeva
NKNicolay E. Kushlinskiy
Nicolay E. Kushlinskiy
MicroRNAs (miRs, miRNAs) are small molecules of 18–22 nucleotides that serve as important regulators of gene expression at the post-transcriptional level. One of the mechanisms through which miRNAs regulate gene expression involves the interaction of their “seed” sequences primarily with 3′-end and more rarely with 5′-end, of mRNA transcribed from target genes. Numerous studies over the past decade have been devoted to quantitative and qualitative assessment of miRNAs expression and have shown remarkable changes in miRNA expression profiles in various diseases. Thus, profiling of miRNA expression can be an important tool for diagnostics and treatment of disease. However, less attention has been paid towards understanding the underlying reasons for changes in miRNA expression, especially in cancer cells. The purpose of this review is to analyze and systematize current data that explains reasons for changes in the expression of miRNAs. The review will cover both transcriptional (changes in gene expression and promoter hypermethylation) and post-transcriptional (changes in miRNA processing) mechanisms of regulation of miRNA expression, as well as effects of endogenous (hormones, cytokines) and exogenous (xenobiotics) compounds on the miRNA expression. The review will summarize the complex multilevel regulation of miRNA expression, in relation to cell type, physiological state of the body and various external factors.

16 July 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
BUBoyarskih Ulyana
Boyarskih Ulyana
Lyudmila F. GulyaevaLyudmila F. Gulyaeva
Lyudmila F. Gulyaeva
AAA. M. Avdalyan
A. M. Avdalyan
AKAndrey Kechin
Andrey Kechin
EKE. A. Khrapov
E. A. Khrapov
Maksim Leonidovich FilipenkoMaksim Leonidovich Filipenko
Maksim Leonidovich Filipenko
Objective: Mutations in TP53 lead to loss of function (LOF) or gain of function (GOF) of the corresponding protein p53 and produce a different effect on the tumor. Our goal was to determine the spectrum of somatic TP53 variants in BRCA1/2 associated high-grade serous ovarian cancer (HGSOC). Methods: The population under study comprised of HGSOCs with pathogenic variants in BRCA1 (n = 78) or BRCA2 (n = 21). Only chemo-naive and platinum-sensitive patients were included in this study. The case group of the IARC database (n = 1249) with HGSOC not stratified by BRCA status was used as a reference. A custom NGS panel was used for sequencing TP53 and mutational hot-spots of other genes, and p53 expression was evaluated by immunohistochemistry for 68 cases of HGSOCs. Results: Somatic TP53 variants (95) or inhibition of wild-type p53 expression (3) were observed in 98 cases. The sample with normal p53 had CDKNA1 variants. The frequency of truncating variants was significantly higher than in the reference cohort (30.3 vs. 21.0%, p = 0.01). Most of the samples (41/68) demonstrated low (or absent) expression of p53, and 17 samples overexpressed p53. LOH was typical for TP53 nonsense variants (14/15). In total, 68/95 samples were LOH positive and showed LOH in all tumorous cells, thus indicating the driver effect of TP53 mutations. Three specimens had KRAS, BAX, APC, and CTNNB1 subclones variants. Conclusion: High frequency of TP53 truncating variants, the low expression of mutant p53, and low incidence of oncogene mutations show potential GOF properties of p53 to be poorly represented in BRCA1/2 associated HGSOC.

1 January 2008
Verified
Book Chapter
Closed access
PDF file
Lyudmila F. GulyaevaLyudmila F. Gulyaeva
Lyudmila F. Gulyaeva
OMOlga N. Mikhailova
Olga N. Mikhailova
Vladimir PustylnyakVladimir Pustylnyak
Vladimir Pustylnyak
IKInessa V. Kim
Inessa V. Kim
AGAlexei V. Gerasimov
Alexei V. Gerasimov
EPEugene V. Pechkovsky
Eugene V. Pechkovsky

1 May 2014 in Life Sciences
Verified
Journal Article
Closed access
MCMikhail Damirovich Chanyshev
Mikhail Damirovich Chanyshev
NKN.I. Kosorotikov
N.I. Kosorotikov
STSergei Titov
Sergei Titov
NKN.N. Kolesnikov
N.N. Kolesnikov
Lyudmila F. GulyaevaLyudmila F. Gulyaeva
Lyudmila F. Gulyaeva

1 December 2018 in Surgical Oncology
Verified
Journal Article
Closed access
GCGalina Chernaya
Galina Chernaya
NMNina Mikhno
Nina Mikhno
TKTatiana Khabalova
Tatiana Khabalova
SSSvetlana Svyatchenko
Svetlana Svyatchenko
LMLyudmila Mostovich
Lyudmila Mostovich
Lyudmila F. GulyaevaLyudmila F. Gulyaeva
Lyudmila F. Gulyaeva

10 January 2006 in The Pharmacogenomics Journal
Verified
Journal Article
Open access
PDF file
OMO N Mikhailova
O N Mikhailova
Lyudmila F. GulyaevaLyudmila F. Gulyaeva
Lyudmila F. Gulyaeva
APA V Prudnikov
A V Prudnikov
AGA V Gerasimov
A V Gerasimov
SKS E Krasilnikov
S E Krasilnikov
Allelic variants of cytochrome P450: CYP1A1, CYP1A2, CYP19 (Aromatase) and II-phase enzyme Sulfotransferase (SULT1A1) genes are associated with a high risk of hormone-dependent cancers. We estimated a frequency of these allelic variants in the female Caucasian population of the Novosibirsk region of Russia and their association with the elevated risk of ovarian and endometrial cancer. A DNA bank of gynecologic oncology patients, patients with benign gynecologic diseases and healthy women was created, and the following single nucleotide polymorphisms (SNPs) were examined: CYP1A1 M1 polymorphism, that is, T264 → C transition in the 3′-noncoding region; CYP1A2*1F polymorphism, that is, C734 → A transversion in CYP1A2 gene; C → T transition (Arg264Cys) in exon 7 of CYP19; SULT1A1*2 polymorphism, that is, G638 → A transition (Arg213His) in SULT1A1 gene. A positive correlation of C allele of CYP1A2*1F and G allele of SULT1A1*2 with hormone-dependent cancers in women was found. Thus, these genes are appropriate candidates for studying the contribution of genetic factors to endocrine disorder and environmentally determined diseases susceptibility. In contrast, no association of CYP19 and CYP1A1 polymorphisms with increased cancer risk was revealed.